

Contents lists available at [SciVerse ScienceDirect](http://SciVerse.ScienceDirect.com)

Seizure

journal homepage: www.elsevier.com/locate/yseiz

Letter to the Editor

***Helicobacter pylori*'s potential association with epilepsy**

Dear Editor,

We have read with interest the study by Asadi-Pooya et al. who concluded that the rate of *Helicobacter pylori* infection (*Hp*-I) was not higher in patients with epilepsy compared to healthy individuals.¹ However, due to problems mainly encountered during recruitment of the patients and controls of this study, the conclusion of this trial might be not reasonable.

It has been reported that the prevalence of *Hp*-I in the city of Shiraz, where the study by Asadi-Pooya et al. was conducted, is very high,^{2,3} regardless of the socioeconomic status, an already established significant factor affecting *Hp* prevalence in the European countries. This means that to prove a difference in *Hp* prevalence between any two groups in Shiraz would require several hundreds or even a few thousands of participants. Instead, Asadi-Pooya et al. presented their results based on a small number of patients and controls (34 and 33, respectively) and therefore the power of their study was too low. Specifically, the study groups were not age-matched. It seems that the control group was about 10 years older than the idiopathic generalized epilepsy (IGE) group and 2–3 years older than the temporal lobe epilepsy (TLE) group. *Hp* prevalence is higher in older individuals, and this explains why *Hp*-I was detected in 72.7% in the control group compared with 61.8% in the IGE and 50% of the TLE group. These differences did not reach a statistical significance due to the very small number of patients recruited, but it is almost certain that the *p* value equal to 0.068 reported would have been significant if the authors had recruited just a few more patients. In that case the control healthy group would have a higher *Hp* prevalence than the epileptic patients, leading to the paradox conclusion that *Hp* might protect against epilepsy.

On the other hand, recent data suggest a probable association between *Hp*-I and epilepsy, especially with poor prognosis.⁴ In this respect, we speculate that *Hp*-I, by inducing proinflammatory cytokine production and blood–brain barrier (BBB) disruption,⁵ also mentioned by the authors,¹ may lead to neuroinflammation and neuronal damage in epilepsy thereby triggering seizures' induction and epilepsy progression.⁵

Conflict of interest

None.

References

1. Asadi-Pooya AA, Dehghani SM, Petramfar P, Emami M, Mahmoodi M. *Helicobacter pylori* infection in patients with epilepsy. *Seizure* 2011 Sep 7 [Epub ahead of print].
2. Hashemi MR, Rahnavardi M, Bikdeli B, Dehghani Zahedani M. *H. pylori* infection among 1000 southern Iranian dyspeptic patients. *World J Gastroenterol* 2006;12:5479–82.
3. Doroudchi M, Dehaghani AS, Ghaderi A. Preferential placental transfer of *Helicobacter pylori* specific IgG. *J Matern Fetal Neonatal Med* 2004;16:297–301.
4. Ozturk A, Ozturk CE, Ozdemirli B, Yucel M, Bahçebaşı T. *Helicobacter pylori* infection in epileptic patients. *Seizure* 2007;16:147–52.
5. Deretzi G, Kountouras J, Gavalas E, Polyzos SA, Zavos C, Klonizakis P, et al. Multiple sclerosis and seizures: possible role of *Helicobacter pylori*. *Eur J Neurol* 2011;18:e116.

Jannis Kountouras*
Georgia Deretzi
Christos Zavos
Emmanuel Gavalas
Stergios A. Polyzos
Philippos Klonizakis
Dimitrios Tsiptsios
Panagiotis Katsinelos
Elizabeth Vardaka
Elena Tsiaousi
Afroditi Tsona

Department of Medicine, Second Medical Clinic,
Aristotle University of Thessaloniki, Ippokration Hospital,
Thessaloniki, Macedonia, Greece

*Corresponding author at: 8 Fanariou St., Byzantio,
551 33 Thessaloniki, Macedonia, Greece.
Tel.: +30 2310 892238; fax: +30 2310 992794

E-mail addresses: czavos@hotmail.com (C. Zavos),
jannis@auth.gr (J. Kountouras).

2 October 2011